

European Prostate Cancer Awareness Day

17 November 2020



EUPROMS study

Deschamps André
Europa Uomo

EUPROMS study

EUROPA UOMO patient reported outcome study

The first ever survey in PCa from patients for patients

EUROPA UOMO 

The Voice of Men with Prostate Cancer in Europe


The questionnaire

- **20 minute online survey for men who have received treatment for prostate cancer**
- **Available in 19 languages**
- **Used validated quality-of-life questionnaires: EPIC-26 and EORTC-QLQ and EQ-5D-5L**
- **Responses were anonymous**

Geographical response

2,943 responses

25 countries



Norway: 506
Sweden: 386
Belgium: 339


Germany: 253
The Netherlands: 244
France: 234
Denmark: 188
UK: 187
Poland: 109

Portugal: 75
Italy: 71
Austria: 66
Finland: 65
Spain: 55
Lithuania: 52

Other (mainly Cyprus): 38
Ireland: 26
Latvia: 11
Hungary: 10
Estonia: 8
Slovak Republic: 8
Switzerland: 7
Czech Republic: 3
Bulgaria: 1
Greece: 1


PCa is not an old men's disease

Age at diagnosis average **64 years**




(G2) How does treatment affect quality of life?

(Quality of life scores*. Lowest score indicates most troublesome effects)



(D1) Which treatments are linked with pain or discomfort?


(% of respondents saying they were in moderate, severe or extreme pain/discomfort at time of survey*)



*EQ-5D-5L questionnaire

(D2) Which treatments are linked with tiredness?


(Respondents who said they have been quite or very tired in the past week*)



*EORTC-QLQ-C30

(D3) Which treatments are linked with insomnia?


(Respondents who said that have had 'quite a bit' or 'very much' trouble sleeping in the past week*)



*EORTC-QLQ-C30

(M4) Which treatments are linked with mental health problems?

(% of respondents saying they were moderately, severely or extremely depressed or anxious at time of survey*)




*EQ-5D-5L questionnaire

(M3) What proportion of men who have been treated for prostate cancer are anxious or depressed?

(At time of survey*)


42% of men say they are anxious or depressed to some extent



*EQ-5D-5L questionnaire

(S1) How is sexual function after different treatments?


(Quality of life scores*. Lowest score indicates worst effects)



Reference group score: 55,8

(S2) How big a problem is sexual functioning?

(All respondents*)




Half of all men responding said that sexual function has been a **moderate or big problem** after treatment

*EPIC-26 scores


(U1) How is continence after different treatments?

(Quality of life scores*. Lowest score indicates worst effects)



(U3) How many pads do men who have been treated usually use?

(All survey respondents*)




Reference group: 7% uses pads

Take home messages

Take-home messages

1. Active surveillance should be considered as the first treatment in order to ensure the best quality of life




Take-home messages

2. Early detection is key

(% of patients with moderate, severe and very severe problems)

Discomfort Tiredness Insomnia Mental health






Awareness of men



Less than 50%

Support for early detection



-  No promotion
-  Partly promotion
-  Promotion

50%

Men die from prostate cancer



Men suffer from prostate cancer



Policy makers you must change it

Thank you for virtual listening

